FindTrial
Sign In

Biomarker exploration in patients undergoing boron neutron capture therapy (BNCT) for malignant melanoma and angiosarcoma.

Biomarker exploration in patients undergoing boron neutron capture therapy (BNCT) for malignant melanoma and angiosarcoma. - Biomarker exploration in patients undergoing boron neutron capture therapy (BNCT) for malignant melanoma and angiosarcoma.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000043564
Enrollment
18
Registered
2021-03-10
Start date
2020-02-04
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant melanoma of skin and angiosarcoma of skin

Interventions

Blood and urine sampling

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Obvious disseminated lesions The lesion has received radiotherapy in excess of 75 Gy. Active lesions/active multiple cancers other than the target lesion Active implantable medical devices such as implantable cardiac pacemakers are implanted History of BNCT treatment

Design outcomes

Primary

MeasureTime frame
Analysis of metabolites (including proteins) and genes in peripheral blood and urine to establish a measurement system for biomarkers of BNCT efficacy—

Countries

Japan

Contacts

Public ContactHiroshi Igaki

National Cancer Center Hospital Department of Radiation Oncology

hirigaki@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026